ArticleEuropean radiology2023

Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.

Zhi-Cheng Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.